GHM Multi-Drugs Rapid Test Panel US – Qualitative Detection of Multiple Drugs of Abuse and Their Metabolites in Human Urine with 5-Minute Results, Customizable Panel Configurations, and Professional Point-of-Care Use

SKU: GHM Multi-Drugs Rapid Test Panel US
Brand: Global Healthcare Medical

Product Overview

Global Healthcare Medical GHM Multi-Drugs Rapid Test Panel US is a lateral flow chromatographic immunoassay designed for the qualitative detection of multiple drugs of abuse and their metabolites in human urine specimens. The kit is intended for use by healthcare professionals as a screening test for the detection of drug abuse.

Drug abuse screening is a critical component of clinical toxicology, workplace safety programs, and public health surveillance. The multi-drug rapid test panel provides a comprehensive screening solution capable of simultaneously detecting a wide range of commonly abused substances from a single urine specimen within minutes. The panel is customizable to accommodate various combinations of drug analytes, including amphetamines (AMP), barbiturates (BAR), benzodiazepines (BZO), buprenorphine (BUP), cocaine (COC), marijuana (THC), methadone (MTD), methamphetamine (MET), methylenedioxymethamphetamine (MDMA), morphine/opiates (MOP/OPI), oxycodone (OXY), phencyclidine (PCP), tricyclic antidepressants (TCA), fentanyl (FYL), ketamine (KET), tramadol (TML), and many more. The test can be configured as a panel device accommodating up to 15 drug test strips in different test configurations, or as an integrated cup format for convenient collection and testing in a single device.

The GHM Multi-Drugs Rapid Test Panel US utilizes a competitive binding immunoassay format. In the test procedure, drugs that may be present in the urine specimen compete with drug conjugate on the test strip for limited antibody binding sites. The test is a rapid, one-step screening tool that provides qualitative preliminary results within minutes, making it suitable for laboratory and point-of-care applications.

The GHM Multi-Drugs Rapid Test Panel US delivers qualitative results in as fast as 5 minutes, supporting rapid clinical decision-making and efficient workflow in point-of-care settings. The test is compatible with human urine specimens, providing a simple and non-invasive sample collection method suitable for a wide range of clinical and workplace settings.

The kit is intended for in vitro diagnostic use and professional use only, suitable for application scenarios including clinical toxicology laboratories, workplace drug testing programs, emergency departments, substance abuse treatment centers, and correctional facilities. The VivaDiag product line is manufactured under an EN ISO 13485 certified quality management system covering in vitro diagnostic test kits and analyzers based on immunochromatography.

Key Features & Benefits

Multi-Drug Panel Detection – Simultaneous Screening for Up to 15+ Drugs

The GHM Multi-Drugs Rapid Test Panel US utilizes a lateral flow chromatographic immunoassay capable of simultaneously detecting multiple drugs of abuse and their metabolites from a single urine specimen. The panel can be configured with various combinations of drug analytes, accommodating up to 15 drug test strips in different test configurations. This multi-panel design supports comprehensive drug screening in a single test, reducing the need for multiple specimen collections and separate testing procedures.

Fast Results – 5 Minutes

The GHM Multi-Drugs Rapid Test Panel US provides qualitative results in as fast as 5 minutes, supporting rapid clinical decision-making and efficient patient workflow in point-of-care settings. Rapid results enable immediate clinical assessment and timely decision-making in workplace and clinical drug testing programs.

Urine Sample Compatibility – Simple and Non-Invasive Collection

The GHM Multi-Drugs Rapid Test Panel US is compatible with human urine specimens, providing a simple and non-invasive sample collection method. The test requires only a small urine volume and is designed for use with the panel dip format or integrated cup format for convenient specimen processing. Specimen collection should be performed in a clean, dry container to avoid contamination.

Clinical Utility – Aid for Detection of Drug Abuse

The GHM Multi-Drugs Rapid Test Panel US is intended for use as a screening test for the detection of drugs of abuse and their metabolites in human urine. The test provides rapid preliminary results, enabling timely clinical decision-making and supporting patient management.

The multi-panel design provides comprehensive screening value across a wide range of commonly abused substances. The test is particularly valuable in clinical toxicology laboratories, workplace drug testing programs, emergency departments, substance abuse treatment centers, and correctional facilities. A positive result at the specified cut-off concentration indicates a preliminary positive result and should be confirmed with a more specific alternative chemical method such as gas chromatography/mass spectrometry (GC/MS) before making clinical or employment decisions.

High Accuracy – Trusted Clinical Performance

The GHM Multi-Drugs Rapid Test Panel US is designed to deliver reliable clinical performance for the qualitative detection of drugs of abuse at specified cut-off concentrations. The test is based on the competitive binding principle, in which drugs in the urine specimen compete with immobilized drug conjugate for limited antibody binding sites, producing results that correlate with the presence or absence of the target analyte at the established cut-off level.

Performance characteristics based on product specifications and industry-standard cut-off concentrations for drugs of abuse testing. The analytical sensitivity of the test is established at the cut-off concentrations listed above. The test provides only a preliminary qualitative result; a more specific alternative chemical method such as GC/MS must be used to obtain a confirmed analytical result. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary results are positive. Negative results may occur if the drug concentration in the specimen is below the cut-off level or if the specimen was collected at a time when the drug is no longer detectable. The detection window varies depending on the drug, dosage, frequency of use, and individual metabolic factors.

ISO 13485 Certified – Quality and Safety Compliance

The VivaDiag product line is manufactured under an EN ISO 13485 certified quality management system, demonstrating compliance with stringent international standards for the design, development, manufacture, and distribution of in vitro diagnostic test kits and analyzers.

CE Marked – European Conformity

The GHM Multi-Drugs Rapid Test Panel US is CE marked for professional in vitro diagnostic use, demonstrating conformity with applicable European regulatory requirements for diagnostic medical devices.

Product Specifications

Important Testing Notes:

• Collect urine specimen in a clean, dry container. Do not use preservatives.

• For optimal results, test the specimen immediately after collection. If testing is delayed, refrigerate at 2–8°C. Specimens may be stored at 2–8°C for up to 48 hours; for longer storage, freeze at -20°C. Avoid repeated freeze-thaw cycles.

• Bring all kit components and specimens to room temperature (18–30°C) prior to testing.

• Remove the test panel from the sealed pouch and use it within one hour.

• Immerse the test strips in the urine specimen or apply urine to the sample well according to the panel format instructions.

• Read results at 5 minutes. Do not interpret results after 10 minutes.

• A colored line in the control region (C) indicates proper test performance. A colored line in a test region (T) indicates a preliminary positive result for that drug.

• A negative result does not rule out drug use; the drug concentration may be below the cut-off level or the drug may no longer be detectable at the time of specimen collection.

• A positive result is preliminary and must be confirmed by a more specific alternative chemical method such as GC/MS before making clinical or employment decisions.

Why Clinical Professionals Choose Global Healthcare Medical

About Global Healthcare Medical

Global Healthcare Medical is dedicated to connecting healthcare providers, retailers, and distributors with high-quality medical devices designed for reliable performance. The GHM Multi-Drugs Rapid Test Panel US is part of our professional diagnostic line, developed to support accurate, efficient, and accessible point-of-care testing in clinical environments.

Our focus is on dependable performance, clear documentation, and responsive support for professional healthcare settings.